As of 2024-10-07, the EV/EBITDA ratio of Oramed Pharmaceuticals Inc (ORMP) is -0.87. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ORMP's latest enterprise value is 11.06 mil USD. ORMP's TTM EBITDA according to its financial statements is -12.66 mil USD. Dividing these 2 quantities gives us the above ORMP EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.3x - 13.1x | 12.6x |
| Forward P/E multiples | 17.4x - 21.3x | 20.1x |
| Fair Price | (3.34) - (1.98) | (3.00) |
| Upside | -242.0% - -184.3% | -227.6% |
| Date | EV/EBITDA |
| 2024-10-07 | -1.05 |
| 2024-10-04 | -0.87 |
| 2024-10-03 | -1.07 |
| 2024-10-02 | -1.00 |
| 2024-10-01 | -1.03 |
| 2024-09-30 | -1.16 |
| 2024-09-27 | -1.29 |
| 2024-09-26 | -1.03 |
| 2024-09-25 | -1.00 |
| 2024-09-24 | -0.87 |
| 2024-09-23 | -0.79 |
| 2024-09-20 | -0.74 |
| 2024-09-19 | -1.26 |
| 2024-09-18 | -1.10 |
| 2024-09-17 | -1.39 |
| 2024-09-16 | -1.29 |
| 2024-09-13 | -1.32 |
| 2024-09-12 | -0.91 |
| 2024-09-11 | -0.97 |
| 2024-09-10 | -1.03 |
| 2024-09-09 | -1.07 |
| 2024-09-06 | -0.87 |
| 2024-09-05 | -0.74 |
| 2024-09-04 | -0.97 |
| 2024-09-03 | -1.07 |
| 2024-08-30 | -1.00 |
| 2024-08-29 | -1.03 |
| 2024-08-28 | -1.03 |
| 2024-08-27 | -1.00 |
| 2024-08-26 | -1.26 |
| 2024-08-23 | -1.29 |
| 2024-08-22 | -1.26 |
| 2024-08-21 | -1.26 |
| 2024-08-20 | -1.03 |
| 2024-08-19 | -0.94 |
| 2024-08-16 | -0.84 |
| 2024-08-15 | -0.87 |
| 2024-08-14 | -0.52 |
| 2024-08-13 | -0.91 |
| 2024-08-12 | -0.78 |
| 2024-08-09 | -0.84 |
| 2024-08-08 | -0.94 |
| 2024-08-07 | -0.42 |
| 2024-08-06 | -0.87 |
| 2024-08-05 | -0.42 |
| 2024-08-02 | -0.84 |
| 2024-08-01 | -0.94 |
| 2024-07-31 | -1.52 |
| 2024-07-30 | -1.13 |
| 2024-07-29 | -1.42 |